ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Factors Associated with Different Survival Functions in Anticoagulated Patients with Chronic Kidney Disease.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo analyze 180-day survival and associated factors in patients with chronic kidney disease (CKD) who initiated anticoagulation therapy during hospitalization.MethodsA survival analysis study was conducted using Kaplan-Meier curves on a retrospective cohort of CKD patients on anticoagulation. Cox regression identified factors associated with survival differences.ResultsThe study included 224 patients (50.90% male, 71.80% > 65 years, 30.80% with atrial fibrillation (AF), and 50% with venous thromboembolism (VTE)). Mortality was 40.63%, with higher survival in the AF group versus VTE (p = 0.0107), CKD stage 3a versus stage 4 (p = 0.0009), and stage 5 versus stage 4 (p = 0.0277). Mortality risk was higher in patients with subsidized healthcare (HR 1.47; 95% CI 1.17-3.12; p = 0.010), cancer (HR 1.77; 95% CI 1.15-2.71; p = 0.008), and VTE (HR 1.87; 95% CI 1.22-2.86; p = 0.004), Arterial hypertension (HR 0.44; 95% CI 0.29-0.68; p = 0.001), coronary artery disease (HR 0.42; 95% CI 0.20-0.48; p = 0.022), and antiplatelet monotherapy (HR 0.56; 95% CI 0.32-0.96; p = 0.037) did not influence survival.ConclusionsCKD patients on anticoagulation therapy have high early mortality. Cancer, subsidized healthcare affiliation, and venous thromboembolism were independent risk factors associated with mortality, whereas hypertension and single antiplatelet therapy were not. This suggests that intensified follow-up and individualized management strategies may be particularly beneficial in these high-risk groups. Larger, prospective studies are needed to optimize anticoagulation management in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.